



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lcyc20>

Intramolecular 1,3-Dipolar Cycloaddition of Azomethine Ylides Leading to Pyrido[2,3-b]quinolines

Judit Tóth^a, Barbara Somfai^a, Gábor Blaskó^b,
András Dancsó^b, László Tóke^a & Miklós Nyerges^a

^a Research Group of the Hungarian Academy of Sciences, Department of Organic Chemical Technology, Technical University of Budapest, Budapest, Hungary

^b EGIS Pharmaceuticals Ltd., Budapest, Hungary

Version of record first published: 01 Jun 2009

To cite this article: Judit Tóth, Barbara Somfai, Gábor Blaskó, András Dancsó, László Tóke & Miklós Nyerges (2009): Intramolecular 1,3-Dipolar Cycloaddition of Azomethine Ylides Leading to Pyrido[2,3-b]quinolines, *Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry*, 39:13, 2258-2270

To link to this article: <http://dx.doi.org/10.1080/00397910802401142>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Intramolecular 1,3-Dipolar Cycloaddition of Azomethine Ylides Leading to Pyrido[2,3-*b*]quinolines

Judit Tóth,¹ Barbara Somfai,¹ Gábor Blaskó,² András Dancsó,²
László Töke,¹ and Miklós Nyerges¹

¹Research Group of the Hungarian Academy of Sciences, Department of Organic
Chemical Technology, Technical University of Budapest, Budapest, Hungary

²EGIS Pharmaceuticals Ltd., Budapest, Hungary

Abstract: A convenient six-step route to the previously unknown 1*H*-pyrrolo[2,3-*f*]benzo[*b*][1,8]naphthyridine ring system using an intramolecular 1,3-dipolar cycloaddition of nonstabilized azomethine ylides has been described.

Keywords: Cycloadditions, heterocycles, tandem reactions, ylides


Quinolines and their derivatives are very important in medicinal chemistry because of their wide occurrence in natural products^[1] and drugs.^[2] Among the quinolines, 2-chloro-3-formyl-quinolines (**1**) occupy a prominent position because they are intermediates for further [*b*]-annulation of a wide variety of rings and for various functional group interconversions.^[3] Beside the large number of quinoline derivatives, the applications of these methodologies have yielded new synthetic approaches for alkaloids such as camptothecin,^[4] luotonin A,^[5] 22-hydroxyacuminatine,^[6] or nothapodytine.^[7]

Recently we have described^[8] the first [*c*]-annulation of this type of quinoline by 1,5-electrocyclization of azomethine ylides,^[9] which gave a direct route to the otherwise hardly accessible pyrrolo[3,4-*c*]quinoline ring system (**2**) (Scheme 1).^[10]

The 2-chloro-3-formylquinolines (**1**) remained popular starting compounds for the synthesis of new heterocycles using intramolecular

Received June 12, 2008.

Address correspondence to Miklós Nyerges, Servier Research Institute of Medicinal Chemistry, H-1031 Budapest, Záhony u. 7. Graphisoft Park, Hungary.
E-mail: miklos.nyerges@hu.netgrs.com




Scheme 1. Synthetic annulations to 2-chloro-3-formylquinolines.

1,3-dipolar cycloadditions of various dipole types.^[11] These results prompted us to study the related reactions of azomethine ylides, which gives direct access to the hitherto unknown hexahydro-1*H*-pyrrolo[2,3-*f*]benzo[*b*][1,8]naphthyridin-4-ones.


RESULTS AND DISCUSSION

The starting quinolines (**1a–c**) were prepared by the method described by Meth-Cohn and Narine from the corresponding acetanilides (**3a–c**) by treatment with the Vilsmeier reagent in a very effective domino reaction (Scheme 2).^[12]

The quinoline ketals (**4a–c**) were reacted with excess of benzylamine in the absence of any solvent at 180 °C to give the expected 2-benzylamino-quinolines, but at the same time the ketal was also replaced by a



Scheme 2. Reagents and conditions: i) $POCl_3$, DMF, 80 °C; and ii) $HOCH_2CH_2OH$, PTSA, benzene, reflux.




Scheme 3. Reagents and conditions: i) PhCH₂NH₂, 180 °C; ii) 5% HCl, THF, rt; and iii) PhCH₂NH₂, NaOBu^t, Pd(OAc)₂, PPh₃, toluene, 180 °C.

benzylimino moiety. The direct reaction of the 3-formyl-quinolines **1a-c** with benzylamine under the same conditions proceeded in much lower yield.

The 3-(benzyliminomethyl)quinolines (**6a-c**) were easily hydrolyzed to the corresponding aldehydes under mild conditions (Scheme 3). Alternatively, in one example, the palladium-catalyzed coupling of benzylamine to ketal-protected quinoline **5c** was also investigated, followed by the hydrolytic removal of the protecting group from **8**, but the overall yield was lower coupled with longer reaction times, so we decided to use the route that applies the neat benzylamine.

The 2-aminoquinolines **7a-c** were acylated with acryloyl chloride in the presence of 4-(dimethylamino)pyridine (DMAP) in dimethyl formamide solution at 80 °C. The nonstabilized azomethine ylides **10** were generated from the aldehydes **9a-c** in refluxing toluene using the method of decarboxylative condensation with sarcosine.^[13] The azomethine ylides intermediates reacted via the expected intramolecular 1,3-dipolar cycloaddition^[14] to the acrylamide double bond to give the tetracyclic hexahydro-1*H*-pyrrolo[2,3-*f*]benzo[*b*][1,8]naphthyridin-4-ones **11a-c** as products, which were isolated in acceptable yields after column chromatography (Scheme 4). The stereochemistry of the isolated cycloadducts (**11**) were proven by nuclear Overhauser effect (NOE) experiments.



Scheme 4. Reagents and conditions: i) $CH_2=CHCOCl$, Et_3N , DMF, DMAP, $80^\circ C$; ii) CH_3NHCH_2COOH , toluene, $110^\circ C$.

In summary, we have explored a convenient reaction sequence that provides a useful route to the previously unknown 1*H*-pyrrolo[2,3-*f*]benzo[*b*][1,8]naphthyridin ring system using an intramolecular 1,3-dipolar cycloaddition of nonstabilized azomethine ylides.

EXPERIMENTAL

General

Melting points were determined on a Gallenkamp apparatus and are uncorrected. Column chromatography was performed using Merck Kieselgel 60, 70–230 mesh, and thin-layer chromatography (TLC) on aluminium sheets coated with Kieselgel 60 F_{254} . Plates were stained with anisaldehyde solution (100 ml glacial acetic acid, 2 ml conc. sulfuric acid, and 1 ml anisaldehyde) and heated at ca. $150^\circ C$. IR spectra were obtained on a Bruker Vector 22 FT-IR instrument. NMR spectra were obtained on Varian Inova 500, Bruker DRX-500, and Bruker 250 instruments. Chemical shifts are given relative to δ_{TMS} . All solvents were purified according to standard procedures.

Synthesis of *N*-Benzyl-3-[(benzylimino)methyl]quinolin-2-amines (6a–c)

General Procedure

The corresponding 3-[1',3'-dioxolane-2'-yl]-2-chloroquinoline (**5a–c**, 20 mmol) was suspended in benzylamine (10 ml), and the reaction mixture was heated at 180 °C for 1 h under an argon atmosphere. The excess of benzylamine was removed with vacuum distillation, and the residue was crystallized from ether to yield the yellow product.

Data for 6a–c

N-Benzyl-3-[(benzylimino)methyl]quinolin-2-amine (**6a**)

Yield: 6.46 g (92%); yellow crystals; mp. 123–124 °C; ¹H NMR (500 MHz, CDCl₃): 9.72 (1H, br s, NH), 8.46 (1H, s, H-4), 7.82 (1H, s, CH=N), 7.52 (6H, m, Ar-H), 7.33 (4H, m, Ar-H), 7.21 (4H, m, Ar-H), 4.84 (2H, d, *J* = 5.5 Hz, NHCH₂-), 4.77 (2H, s, NCH₂); ¹³C NMR (125 MHz, CDCl₃): 163.0 (CH), 147.7 (q), 142.0 (CH), 140.0 (q), 139.6 (q), 134.7 (q), 129.7 (CH), 128.7 (2 × CH), 128.6 (2 × CH), 127.9 (2 × CH), 127.2 (2 × CH), 126.4 (CH), 126.1 (CH), 125.1 (CH), 121.1 (q), 121.5 (CH), 121.3 (CH), 118.1 (q), 64.8 (CH₂), 44.7 (CH₂); IR (KBr, cm⁻¹): 3220, 3061, 3017, 2859, 1635, 1600, 1571, 1536, 1499, 1451, 1412, 1394, 1164, 1141, 1016. HRMS: calcd. 351.1735 for C₂₄H₂₁N₃; found 351.1734. H, 6.02; C, 82.02; N, 11.96.

N-Benzyl-3-[(benzylimino)methyl]-6-methoxyquinolin-2-amine (**6b**)

Yield: 7.31 g (96%); yellow crystals; mp 130 °C; ¹H NMR (500 MHz, CDCl₃): 9.56 (1H, br s, NH), 8.47 (1H, s, H-4), 7.81 (1H, s, CH=N), 7.65 (1H, d, *J* = 8.0 Hz, H-8), 7.42 (2H, d, *J* = 7.5 Hz, Ph-H), 7.28 (9H, m, Ar-H), 6.93 (d, 1H, *J* = 2.5 Hz, H-5), 4.86 (2H, d, *J* = 5.2 Hz, NHCH₂-), 4.78 (2H, s, NCH₂), 3.85 (3H, s, CH₃); ¹³C NMR (125 MHz, CDCl₃): 162.6 (CH), 154.5 (q), 154.1 (q), 141.7 (CH), 138.9 (q), 128.6 (q), 128.5 (2 × CH), 128.4 (q), 128.3 (2 × CH), 127.8 (2 × CH), 127.7 (2 × CH), 127.5 (CH), 127.0 (CH), 126.8 (CH), 122.9 (CH), 122.4 (q), 116.8 (q), 106.5 (CH), 65.0 (CH₂), 55.5 (CH₃), 45.0 (CH₂); IR (KBr, cm⁻¹): 3221, 3060, 3027, 2895, 2859, 1638, 1602, 1572, 1531, 1495, 1452, 1402, 1373, 1339, 1232, 1166, 1118, 1079, 1033. HRMS: calcd. 381.1841 for C₂₅H₂₃N₃O; found: 381.1830. H, 6.08; C, 78.71; N, 11.02; O, 4.19.

N-Benzyl-3-[(benzylimino)methyl]-8-methylquinolin-2-amine (**6c**)

Yield: 6.57 g (90%); yellow crystals; mp 118 °C; ¹H NMR (500 MHz, CDCl₃): 9.67 (1H, br t, *J* = 5.4 Hz, NH), 8.47 (1H, s, H-4), 7.84 (1H, s, CH=N), 7.42 (4H, m, Ar-H), 7.26 (8H, m, Ar-H), 7.06 (1H, t, *J* = 7.3 Hz, H-6), 4.87 (2H, d, *J* = 5.4 Hz, NHCH₂-), 4.79 (2H, s, NCH₂), 2.62 (3H, s, CH₃); ¹³C NMR (125 MHz, CDCl₃): 162.8 (CH), 154.2 (q), 147.4 (q), 142.9 (CH), 140.2 (q), 139.1 (q), 134.1 (q), 131.1 (CH), 128.5 (2 × CH), 128.3 (2 × CH), 127.8 (2 × CH), 127.6 (2 × CH), 127.0 (CH), 126.6 (CH), 125.9 (CH), 121.9 (q), 121.3 (CH), 116.3 (q), 64.9 (CH₂), 44.9 (CH₂), 17.9 (CH₃); IR (KBr, cm⁻¹): 3201, 3028, 2941, 2906, 2869, 1641, 1618, 1579, 1531, 1494, 1469, 1452, 1415, 1397, 1375, 1335, 1250, 1176, 1077, 1026. HRMS: calcd. 365.1891 for C₂₅H₂₃N₃; found: 365.1901. H, 6.34; C, 82.16; N, 11.50.

Synthesis of 2-(Benzylamino)quinoline-3-carbaldehydes (**7a–c**)

General Procedure

The corresponding *N*-benzyl-3-[(benzylimino)methyl]quinolin-2-amine (**6**, 10 mmol) was dissolved in tetrahydrofuran (50 ml), and 5% aqueous hydrochloric acid (10 ml) was added. The reaction mixture was stirred at room temperature for 2 h and then water (50 ml) and ether (50 ml) were added. The organic phase was washed with water (2 × 50 ml) and brine (50 ml), dried over MgSO₄, and evaporated in vacuo. The residue was crystallized from aqueous ethanol.

Data for **7a–c**2-(Benzylamino)quinoline-3-carbaldehyde (**7a**)

Yield: 1.44 g (55%); yellow crystals; mp 144 °C; ¹H NMR (300 MHz, DMSO-d₆): 10.05 (1H, s, CHO), 8.81 (1H, s, H-4), 8.72 (1H, br s, NH), 7.91 (1H, d, *J* = 7.8 Hz, H-5), 7.74 (1H, d, *J* = 7.5 Hz, Ph-2' and 6'H), 7.45 (4H, m, Ph-H and H-6 and H-7), 7.28 (1H, d, *J* = 7.8 Hz, H-8), 4.89 (2H, br s, CH₂); ¹³C NMR (125 MHz, CDCl₃): 194.2 (CH), 153.3 (q), 150.1 (q), 139.0 (q), 134.2 (q), 130.0 (CH), 128.8 (q), 128.6 (2 × CH), 127.9 (CH), 127.7 (2 × CH), 127.2 (CH), 123.3 (CH), 121.6 (CH), 117.6 (CH), 44.3 (CH₂); IR (KBr, cm⁻¹): 3351, 2963, 2851, 1672, 1622, 1601, 1568, 1536, 1493, 1451, 1416, 1393, 1164, 1143, 1026. HRMS: calcd. 262.1106 for C₁₇H₁₄N₂O; found: 262.1111. H, 5.38; C, 77.84; N, 10.68; O, 6.10.

2-(Benzylamino)-6-methoxyquinoline-3-carbaldehyde (**7b**)

Yield: 1.96 g (67%); yellow crystals; mp 153 °C; ^1H NMR (300 MHz, CDCl_3): 9.89 (1H, s, CHO), 8.20 (1H, br s, NH), 8.05 (1H, s, H-4), 7.59 (1H, d, $J=8.0$ Hz, H-8), 7.30 (6H, m, Ph-H and H-7), 6.91 (1H, s, H-5), 4.83 (s, 2H, NCH_2), 3.83 (3H, s, OMe); ^{13}C NMR (125 MHz, CDCl_3): 192.9 (CH), 154.7 (q), 153.3 (q), 146.8 (CH), 139.3 (q), 128.3 ($2 \times \text{CH}$), 127.9 (q), 127.8 (CH), 127.6 ($2 \times \text{CH}$), 126.9 (CH), 125.7 (CH), 121.9 (q), 116.9 (q), 106.4 (CH), 55.3 (CH_3), 44.4 (CH_2); IR (KBr, cm^{-1}): 3417, 3268, 2965, 2676, 1682, 1615, 1588, 1514, 1479, 1461, 1400, 1378, 1347, 1292, 1236, 1209, 1171, 1134, 1024. HRMS: calcd. 292.1211 for $\text{C}_{18}\text{H}_{16}\text{N}_2\text{O}_2$; found: 292.1214. H, 5.52; C, 73.95; N, 9.58; O, 10.95.

2-(Benzylamino)-8-methylquinoline-3-carbaldehyde (**7c**)

Yield: 1.60 g (58%); yellow crystals; mp 139–140 °C; ^1H NMR (500 MHz, CDCl_3): 9.74 (1H, s, CHO), 8.32 (1H, t, $J=5.5$ Hz, NH), 7.88 (1H, s, H-4), 7.38 (1H, t, $J=7.1$ Hz, Ph-4'H), 7.36 (2H, t, $J=7.1$ Hz, Ph-2' and 6'H), 7.22 (3H, m, H-5, Ph-3' and 5'H), 7.14 (1H, d, $J=8.0$ Hz, H-7), 6.99 (1H, t, $J=8.0$ Hz, H-6), 7.00 (1H, t, $J=7.7$ Hz, H-6), 4.78 (2H, d, $J=5.5$ Hz, CH_2), 2.53 (3H, s, CH_3); ^{13}C NMR (125 MHz, CDCl_3): 192.8 (CH), 153.1 (q), 149.4 (q), 148.2 (CH), 139.5 (q), 134.3 (q), 133.1 (CH), 128.2 ($2 \times \text{CH}$), 127.7 ($2 \times \text{CH}$), 126.8 ($2 \times \text{CH}$), 121.9 (CH), 121.4 (q), 116.6 (q), 44.4 (CH_2), 17.8 (CH_3); IR (KBr, cm^{-1}): 3375, 3027, 2915, 1663, 1618, 1534, 1466, 1451, 1416, 1408, 1397, 1375, 1360, 1303, 1167, 1155, 1077. HRMS: calcd. 276.1262 for $\text{C}_{18}\text{H}_{16}\text{N}_2\text{O}$; found: 276.1241. H, 5.84; C, 78.24; N, 10.14; O, 5.79.

N-Benzyl-3-(1,3-dioxolan-2-yl)-8-methylquinolin-2-amine (**8**)

3-[1',3'-Dioxolane-2'-yl]-8-methyl-2-chloroquinoline (**4c**, 2.50 g, 10 mmol) was dissolved in dry toluene (50 ml) and benzylamine (1.18 g, 1.21 ml, 11 mmol); sodium *tert*-butoxide (0.96 g, 11 mmol) and triphenylphosphine (0.39 g, 1.5 mmol) were added. The reaction was flushed with argon and kept under an argon atmosphere. Then, palladium(II) acetate (0.18 g, 0.8 mmol) was added, and the reaction mixture was heated under reflux for 8 h. Palladium was filtered off using a pad of Celite[®]. The remaining solution was washed with water (2×25 ml) and brine (25 ml), dried over MgSO_4 , and evaporated in vacuo. The residue was purified by column chromatography (eluent hexane–ethyl acetate 1:1) to yield the title product (1.50 g, 47%).

^1H NMR (500 MHz, CDCl_3): 7.88 (1H, s, H-4), 7.37 (3H, m, Ar-H), 7.28 (4H, m, Ar-H), 7.23 (1H, t, $J = 7.2$ Hz, H-5), 6.05 (1H, br s, NH), 5.81 (1H, s, CH), 4.82 (2H, d, $J = 5.5$ Hz, NHC_2), 3.95 (4H, m, $\text{OCH}_2\text{-CH}_2\text{O}$), 2.61 (3H, s, CH_3); ^{13}C NMR (125 MHz, CDCl_3): 153.2 (q), 146.6 (q), 140.3 (q), 135.0 (CH), 134.0 (q), 129.7 (CH), 128.4 ($2 \times \text{CH}$), 127.7 ($2 \times \text{CH}$), 126.7 (CH), 125.9 (CH), 122.3 (q), 121.7 (CH), 118.6 (q), 101.9 (CH), 64.7 ($2 \times \text{CH}_2$), 45.2 (CH_2), 17.8 (CH_2); IR (KBr, cm^{-1}): 3442, 3061, 2980, 2891, 1628, 1598, 1571, 1526, 1491, 1412, 1368, 1330, 1262, 1208, 1179, 1136, 1100, 1037; HRMS: Calcd: 320.1524 for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_2$; found: 320.1544. H, 6.29; C, 74.98; N, 8.74; O, 9.99.

2-(Benzylamino)-8-methylquinoline-3-carbaldehyde (7c)

Amine (**8**, 0.64 g, 2 mmol) was dissolved in tetrahydrofuran (10 ml), and 5% aqueous hydrochloric acid (2 ml) was added. The reaction mixture was stirred at room temperature for 2 h, and then water (10 ml) and ether (10 ml) were added. The organic phase was washed with water (2×10 ml) and brine (10 ml), dried over MgSO_4 , and evaporated in vacuo. The residue was purified by flash chromatography (eluent hexane–ethyl acetate 1:1) to yield the title product (**7c**, 0.29 g, 52%).

Synthesis of Acrylamides (9a–c), General Procedure

The corresponding 2-(benzylamino)quinoline-3-carbaldehyde (**7**, 3.5 mmol) was dissolved in dry DMF (10 ml), and 4-dimethylaminopyridine (10 mg) and triethylamine (0.38 g, 0.54 ml, 3.8 mmol) were added. The resulting solution was heated to 80°C under an argon atmosphere, and acryloyl chloride (0.34 g, 0.31 ml, 3.8 mmol) was added dropwise. The reaction mixture was kept at 80°C for 15 h, then water (20 ml) and ethyl acetate (25 ml) were added. The organic phase was washed by further portions of water (3×10 ml) and brine (15 ml), dried over MgSO_4 , and evaporated in vacuo. The residue was purified by column chromatography (eluent hexane–ethyl acetate 1:1) to yield the title products.

Data for 9a–c

N-Benzyl-*N*-(3-formylquinolin-2-yl)prop-2-enamide (9a)

Yield: 0.49 g (44%); pale yellow oil; ^1H NMR (300 MHz, CDCl_3): 8.67 (1H, s, CHO), 8.11 (1H, s, qui-H-4), 7.96 (1H, d, $J = 8.0$ Hz, qui-H-8),

7.67 (1H, t, $J = 8.0$ Hz, qui-H-7), 7.23 (8H, m, Bn-H, H-1, qui-H-5 and 6), 6.47 (1H, d, $J = 16.5$ Hz, H-2), 5.83 (1H, br m, PhCH₂), 5.36 (2H, br m, H-2 and PhCH₂); ¹³C NMR (125 MHz, CDCl₃): 187.7 (CH), 172.0 (q), 161.1 (q), 152.8 (q), 140.1 (CH), 132.8 (q), 130.7 (CH₂), 130.4 (CH), 129.3 (CH), 128.9 (2 × CH), 128.8 (2 × CH), 128.0 (CH), 127.7 (CH), 126.5 (CH), 124.1 (q), 122.2 (CH), 120.2 (q), 53.3 (CH₂); IR (KBr, cm⁻¹): 3063, 3031, 2927, 1698, 1618, 1586, 1536, 1495, 1408, 1191, 1080, 1029. HRMS: calcd. 316.1211 for C₂₀H₁₆N₂O₂; found: 316.1211. H, 5.10; C, 75.93; N, 8.85; O, 10.11.

N-Benzyl-*N*-(3-formyl-6-methoxyquinolin-2-yl)prop-2-enamide (**9b**)

Yield: 0.63 g (52%); pale yellow oil; ¹H NMR (300 MHz, CDCl₃): 9.42 (1H, s, CHO), 8.47 (1H, s, qui-H-4), 7.94 (1H, d, $J = 7.5$ Hz, qui-H-8), 7.46 (1H, d, $J = 7.5$ Hz, qui-H-7), 7.19 (1H, s, qui-H-5), 7.15 (6H, m, Bn-H and H-1), 6.36 (1H, d, $J = 17$ Hz, H-2), 5.69 (2H, br m, H-2 and PhCH₂), 5.47 (1H, br s, PhCH₂), 3.82 (3H, s, OMe); ¹³C NMR (125 MHz, CDCl₃): 187.9 (CH), 171.2 (q), 166.0 (q), 159.0 (q), 150.6 (q), 146.2 (q), 138.8 (CH), 132.7 (CH), 130.8 (CH), 129.8 (CH₂), 129.9 (2 × CH), 128.3 (2 × CH), 127.3 (q), 126.8 (CH), 126.7 (q), 126.5 (CH), 106.0 (CH), 55.7 (CH₃), 52.2 (CH₂); IR (KBr, cm⁻¹): 3352, 2998, 2924, 2879, 1697, 1665, 1613, 1542, 1464, 1412, 1257, 1192, 1112, 1084, 1055, 1025. HRMS: calcd: 346.1317 for C₂₁H₁₈N₂O₃; found: 346.1319. H, 5.24; C, 72.82; N, 8.09; O, 13.86.

N-Benzyl-*N*-(3-formyl-8-methylquinolin-2-yl)prop-2-enamide (**9c**)

Yield: 0.67 g (58%); pale yellow oil; ¹H NMR (300 MHz, CDCl₃): 8.65 (1H, s, CHO), 7.85 (1H, s, qui-H-4), 7.77 (2H, m, H-1 and qui-H-4), 7.51 (2H, m, H-5 and H-6), 7.28 (5H, m Bn-H), 6.47 (1H, d, $J = 16.6$ Hz, H-2), 5.60 (2H, br m, H-2 and PhCH₂), 5.37 (1H, br s, PhCH₂), 2.76 (3H, s, Me); ¹³C NMR (125 MHz, CDCl₃): 182.9 (CH), 165.2 (q), 164.0 (q), 145.6 (q), 143.6 (q), 142.0 (CH), 131.6 (q), 130.4 (CH), 128.9 (CH), 128.6 (2 × CH), 128.2 (CH₂), 127.8 (2 × CH), 127.2 (CH), 126.8 (CH), 125.4 (CH), 122.5 (q), 121.2 (q), 52.3 (CH₂), 17.5 (CH₃); IR (KBr, cm⁻¹): 3364, 3031, 2924, 2869, 1697, 1668, 1615, 1539, 1487, 1467, 1410, 1254, 1192, 1081, 1056, 1029. HRMS: calcd. 330.1368 for C₂₁H₁₈N₂O₂; found: 330.1360. H, 5.49; C, 76.34; N, 8.48; O, 9.69.

Intramolecular 1,3-Dipolar Cycloaddition, General Procedure

The corresponding aldehyde (**9**, 1 mmol) was dissolved in toluene (25 ml), and sarcosine (0.18 g, 2 mmol) was added. The reaction mixture was

refluxed for 6 h under an argon atmosphere. The water formed was removed by the aid of a Dean–Stark trap. After completion of the reaction, the reaction mixture was filtered through a pad of Celite® and the solvent was evaporated in vacuo. After column chromatography (eluent hexane–ethyl acetate 1:1), the product was crystallized from ether.

Data for 11a–c

5-Benzyl-1-methyl-2,3,3a,4,5,11b-hexahydro-1*H*-pyrrolo[2,3-*f*]benzo[*b*][1,8]naphthyridin-4-one (**11a**)

White powder (0.23 g, 66%), mp 194–195 °C; ¹H NMR (250 MHz, CDCl₃): 7.83 (1H, d, *J* = 9.2 Hz, H-7), 7.81 (1H, s, H-11), 7.63 (1H, d, *J* = 9.2 Hz, H-10), 7.55 (1H, t, *J* = 9.2 Hz, H-8), 7.45 (2H, d, *J* = 7.6 Hz, Bn-2' and 6'H), 7.33 (1H, t, *J* = 9.2 Hz, H-9), 7.12 (3H, m, Bn-CH), 5.49 (2H, s, PhCH₂), 3.15 (2H, m, H-11*b* and H-3*a*), 3.01 (1H, m, H-2), 2.70 (1H, m, H-2), 2.26 (2H, m, H-3), 2.14 (3H, s, NMe); ¹³C NMR (125 MHz, CDCl₃): 169.5 (q, C-4), 148.7 (q, C-5*a*), 145.8 (q, C-6*a*), 139.0 (q, Bn-1'C), 138.5 (q, C-7), 129.7 (CH, C-11), 128.3 (2 × CH, CH, Bn-CH), 127.9 (2 × CH, Bn-CH and H-9), 126.9 (CH, H-7), 126.5 (CH, H-8), 124.9 (CH, H-6), 120.2 (q, C-10*a*), 64.7 (CH, C-11*b*), 53.8 (CH₂, Bn), 44.4 (CH₂, C-2), 44.0 (CH, C-3*a*), 39.2 (NCH₃), 25.6 (CH₂, C-3); IR (KBr, cm⁻¹): 3061, 3030, 2957, 2926, 2854, 1668, 1623, 1573, 1496, 1441, 1409, 1385, 1294, 1218, 1168, 1128, 1087, 1028. HRMS: calcd. 343.1684 for C₂₂H₂₁N₃O; found: 343.1672. H, 6.16; C, 76.94; N, 12.24; O, 4.66.

5-Benzyl-9-methoxy-1-methyl-2,3,3a,4,5,11b-hexahydro-1*H*-pyrrolo[2,3-*f*]benzo[*b*][1,8]naphthyridin-4-one (**11b**)

White powder (0.27 g, 72%), mp 201–203 °C; ¹H NMR (300 MHz, CDCl₃): 7.79 (1H, s, H-11), 7.53 (2H, d, *J* = 7.2 Hz, Bn-2' and 6'H), 7.30 (dd, 1H, *J* 3.0 and 9.0 Hz, H-8), 7.29 (3H, m, Bn-H), 7.17 (1H, d, *J* = 9.0 Hz, H-7), 7.5 (1H, d, *J* = 3.0 Hz, H-10), 5.54 (2H, s, PhCH₂), 3.90 (3H, s, OMe), 3.22 (2H, m, H-11*b* and H-3*a*), 3.15 (1H, m, H-2), 2.78 (1H, m, H-2), 2.30 (2H, m, H-3), 2.24 (3H, s, NMe); ¹³C NMR (125 MHz, CDCl₃): 172.0 (q, C-4), 156.8 (q, C-9), 148.4 (q, C-5*a*), 142.3 (q, C-6*a*), 138.6 (q, Bn-1'C), 136.7 (q, C-10*a*), 129.5 (CH, C-11), 128.5 (2 × CH, Bn-C), 128.0 (2 × CH, Bn-C), 126.6 (CH, Bn-4'C), 125.6 (CH, C-7), 122.0 (CH, C-8), 118.3 (q, C-11*a*), 105.3 (CH, C-10), 65.0 (CH, C-11*b*), 55.5 (OCH₃), 54.1 (CH₂, Bn), 44.5 (CH₂, C-2), 44.2 (CH, C-3*a*), 39.6 (NCH₃), 25.8 (CH₂, C-3); IR (KBr, cm⁻¹): 3056,

2925, 2834, 2808, 2771, 1666, 1609, 1504, 1458, 1436, 1398, 1374, 1262, 1232, 1214, 1201, 1163, 1100, 1078, 1029. HRMS: calcd. 373.1790 for $C_{23}H_{23}N_3O_2$; found: 373.1792. H, 6.21; C, 73.97; N, 11.25; O, 8.57.

5-Benzyl-1,7-dimethyl-2,3,3a,4,5,11b-hexahydro-1*H*-pyrrolo[2,3-*f*]benzo[*b*][1,8]naphthyridin-4-one (**11c**)

White powder (0.15 g, 41%), mp 194–195 °C; 1H NMR (250 MHz, $CDCl_3$): 7.83 (1H, s, H-11), 7.45 (5H, m, Ar-H), 7.20 (3H, m, Ar-H), 5.60 (1H, d, $J = 14.2$ Hz, $PhCH_2$), 5.53 (1H, d, $J = 14.2$ Hz, $PhCH_2$), 3.19 (1H, d, $J = 5.6$ Hz, H-11*b*), 3.09 (1H, m, H-3*a*), 3.74 (2H, m, H-2), 2.66 (3H, s, Ar- CH_3), 2.28 (2H, m, H-3), 2.17 (3H, s, NCH_3); ^{13}C NMR (125 MHz, $CDCl_3$): 172.3 (q, C-4), 148.9 (q, C-5*a*), 145.3 (q, C-6*a*), 138.5 (q, Bn-1' C), 138.0 (CH, C-11), 136.1 (q, C-7), 130.0 (CH, C-8), 128.1 (2 \times CH, Bn-CH), 128.0 (2 \times CH, Bn-CH), 126.6 (CH, Bn-4' C), 124.9 (CH, C-10), 124.7 (CH, C-9), 117.6 (q, C-10*a*), 64.8 (CH, C-11*b*), 54.0 (CH_2 , Bn), 44.8 (CH_2 , C-2), 44.1 (CH, C-3*a*), 39.4 (NCH_3), 25.7 (CH_2 , C-3), 18.1 (CH_3); IR (KBr, cm^{-1}): 3027, 2938, 2835, 2778, 1666, 1622, 1497, 1476, 1449, 1433, 1411, 1381, 1362, 1337, 1289, 1237, 1221, 1160, 1104, 1077, 1035. HRMS: calcd. 357.1841 for $C_{23}H_{23}N_3O$; found: 357.1850. H, 6.49; C, 77.28; N, 11.76; O, 4.48.

ACKNOWLEDGMENTS

This work was financially supported by the National Fund for Science and Research, Hungary (OTKA Project No. T 046196). A grant from the EGIS Pharmaceuticals provided to J. T. is gratefully appreciated.

REFERENCES

1. (a) Michael, J. P. Quinoline, quinazoline, and acridone alkaloids. *Nat. Prod. Rep.* **2004**, 650–668; (b) Michael, J. P. Quinoline, quinazoline, and acridone alkaloids. *Nat. Prod. Rep.* **2003**, 476–493.
2. (a) Alhaider, A. A.; Abdelkader, M. A.; Lien, E. J. Design, synthesis, and pharmacological activities of 2-substituted 4-phenylquinolines as potential antidepressant drugs. *J. Med. Chem.* **1985**, 28, 1394–1398; (b) Campbell, S. F.; Hardstone, J. D.; Palmer, M. J. 2,4-Diamino-6,7-dimethoxyquinoline derivatives as α -adrenoceptor antagonists and antihypertensive agents. *J. Med. Chem.* **1988**, 31, 1031–1035; (c) Wu, D. Towards new anticancer drugs: A decade of advances in synthesis of camptothecins and related alkaloids. *Tetrahedron* **2003**, 59, 8649–8687.
3. Meth-Cohn, O. *Heterocycles* **1993**, 35, 539–557.

4. (a) Rigby, J. H.; Danca, D. M. *Tetrahedron Lett.* **1997**, *38*, 4969–4984; (b) Leue, S.; Miao, W.; Kanazawa, A.; Génisson, Y.; Garçon S.; Greene A. E. *J. Chem. Soc., Perkin Trans. 1*, **2001**, 2903–2905; (c) Comins, D. L.; Nolan, J. M. *Org. Lett.* **2001**, *3*, 1611–1615.
5. (a) Toyota, M.; Komori C.; Ihara, M. *Heterocycles* **2002**, *56*, 101–104; (b) Chavan, S. P.; Sivappa, R. *Tetrahedron Lett.* **2004**, *45*, 3113–3115; (c) Chavan, S. P.; Sivappa, R. *Tetrahedron* **2004**, *60*, 9931–9935; (d) Harayama, T.; Morikami, Y.; Shigeta, Y.; Abe, H.; Takeuchi, Y. *Synlett* **2003**, 847–848.
6. Ma, Z.; Lee, D. Y. Z. *Tetrahedron Lett.* **2004**, *45*, 6721–6723.
7. Carles, L.; Narkunan, K.; Penlou, S.; Rousset, L.; Bouchu, D.; Ciufolini, M. A. *J. Org. Chem.* **2002**, *67*, 4304–4308.
8. (a) Pintér, Á.; Nyerges, M.; Virányi, A.; Töke, L. Synthesis of pyrrolo[3,4-*c*]quinolines by 1,5-electrocyclisation of non-stabilised azomethine ylides. *Tetrahedron Lett.* **2003**, *44*, 2343–2346; (b) Nyerges, M.; Pintér, Á.; Virányi, A.; Blaskó, G.; Töke, L. Synthesis of pyrrolo[3,4-*c*]quinolines by 1,5-electrocyclisation of non-stabilised azomethine ylides. *Tetrahedron* **2005**, *61*, 8199–8205.
9. For excellent reviews on 1,5-dipolar cyclizations, see (a) Taylor, E. C.; Turchi, I. *J. Chem. Rev.* **1979**, *79*, 181–231; (b) Huisgen, R. *Angew. Chem., Int. Ed. Engl.* **1980**, *19*, 947–1034.
10. There have been only a few reports on the preparation of pyrrolo[3,4-*c*]quinolines: (a) Horner, L. *Justus Liebigs Ann. Chem.* **1941**, *548*, 117–146; (b) Roy, R. B.; Swan, G. A. *J. Chem. Commun.* **1968**, 1445–1446; (c) Roy, R. B.; Swan, G. A.; *J. Chem. Soc. C* **1969**, 1886–1891; (d) Murata, G.; Satoru, H.; Teramoto, K.; Miura, M.; Nomura, M.; *Heterocycles* **1993**, *36*, 2147–2153; (e) Swan, G. A.; Roy, R. B.; Khandelwal, G. D. *J. Chem. Soc.* **1974**, 891–896; (f) Jones, K.; Wilkinson, J. *J. Chem. Soc., Chem. Commun.* **1992**, 1767–1768; (g) Veenstra, S. J.; Fortgens, R.; Vijn, R. J.; Jong, B. S.; Speckamp, W. N. *Tetrahedron* **1987**, *43*, 1147–1156; (h) Gündel, W.-F.; Bohnert, S. Z. *Naturforsch.* **1985**, *40b*, 1409–1410; (g) Virányi, A.; Nyerges, M.; Blaskó, G.; Töke L. *Synthesis* **2003**, 2655–2660.
11. (a) Kalita, P. K.; Baruah, B.; Bhuyan, P. J. *Tetrahedron Lett.* **2006**, *47*, 7779–7782; (b) Devi, I.; Baruah, B.; Bhuyan, P. J. α -Cyclisation of tertiary amines: Synthesis of some novel annelated quinolines via a three-component reaction under solvent-free conditions. *Synlett* **2006**, 2593–2596; (c) Baruah, B.; Deb, M. L.; Bhuyan, P. J. A novel three-component reaction: Synthesis of some complex annelated quinolines from simple acetanilides and via 1,3-dipolar cycloaddition of azide to nitrile. *Synlett* **2007**, 1873–1876.
12. (a) Meth-Cohn, O.; Narine, B. Versatile new synthesis of quinolines, thienopyridines, and related fused pyridines. *Tetrahedron Lett.* **1978**, *19*, 2045–2048; (b) Meth-Cohn, O.; Narine, B.; Tarnowski, B. A versatile new synthesis of quinolines, thienopyridines, and related fused pyridines 5: The synthesis of 2-chloroquinoline-3-carbaldehydes. *J. Chem. Soc., Perkin Trans. 1*, **1981**, 1520–1530.
13. (a) Tsuge, O.; Kanemasa, S.; Ohe, M.; Takenaka, S. Simple generation of nonstabilized azomethine ylides through decarboxylative condensation of

- α -amino acids with carbonyl compounds via 5-oxazolidone intermediates. *Bull. Chem. Soc. Jpn.* **1987**, *60*, 4079–4089; (b) Nyerges, M.; Balázs, L.; Bitter, I.; Kádas, I.; Kövesdi, I.; Töke, L. *trans*-3-Aryl-4-nitro-pyrrolidines via 1,3-dipolar cycloaddition of nonstabilized azomethine ylide to β -nitro-styrenes. *Tetrahedron* **1995**, *51*, 6783–6788; (c) Arany, A.; Groundwater, P. W.; Nyerges, M. 1,7-Electrocyclization of nonstabilised azomethine ylides *Tetrahedron Lett.* **1998**, *39*, 3267–3268.
14. (a) Pandey, G.; Banerjee, P.; Gadre, S. R. *Chem. Rev.* **2006**, *106*, 4484–4517; (b) Coldham, I.; Hufton, R. *Chem. Rev.* **2005**, *105*, 2765–2810.